title: Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease.
abstract: Alzheimer's disease (AD), the most common human neurodegenerative disease, is characterized pathologically by numerous deposits of amyloid plaques in the brain. Systemic administration of clioquinol (CQ) and inoculation with amyloid-beta42 (Aβ42) vaccines have been demonstrated to significantly inhibit deposits of amyloid in AD brains. However, each of these treatments has also been reported to be neurotoxic. The generation of transgenic mice models of AD has made it possible to study aspects of this disease employing experimental animals. In the present study, we investigated the efficacy and toxicity of CQ and Aβ42 vaccine in a transgenic AD (APP/PS1) mouse model. Our results confirmed that both CQ and Aβ42 vaccine were effective in significantly reducing the deposits of amyloid in the brains of transgenic AD mice. We also report here that systemic CQ induces myelinopathies in the dorsal lateral geniculate nucleus (DLG), which was almost devoid of amyloid plaques and is the primary site of retinal efferent projections via the optic nerve. This is the first report that systemic administration of CQ causes myelinopathies in the central nervous system (CNS) of a transgenic AD mouse model as well as wild-type mice. Inoculation with an Aβ42 vaccine was also found, for the first time, to result in a significant increase in plaque-independent astrocytic hyperplasia in the dorsal part of the lateral septal nucleus (LSD) which was also devoid of plaques, reflecting potential brain inflammatory processes.
authors.affiliation: Division of Neurotoxicology, National Center for Toxicological Research NCTR/FDA, Jefferson, AR 72079, USA.
authors.forename: Yi-Hong
authors.initials: YH
authors.lastname: Zhang
authors.forename: James
authors.initials: J
authors.lastname: Raymick
authors.forename: Sumit
authors.initials: S
authors.lastname: Sarkar
authors.forename: Debomoy K
authors.initials: DK
authors.lastname: Lahiri
authors.forename: Balmiki
authors.initials: B
authors.lastname: Ray
authors.forename: David
authors.initials: D
authors.lastname: Holtzman
authors.forename: Melanie
authors.initials: M
authors.lastname: Dumas
authors.forename: Larry C
authors.initials: LC
authors.lastname: Schmued
mesh_terms: D000544:Alzheimer Disease / Q000150:complications / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000097:blood / Q000276:immunology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D007464:Clioquinol / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004660:Encephalitis / Q000209:etiology / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005829:Geniculate Bodies / Q000378:metabolism / Q000473:pathology; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics; D009186:Myelin Sheath / Q000187:drug effects / Q000473:pathology; D010446:Peptide Fragments / Q000097:blood / Q000276:immunology*; D058225:Plaque, Amyloid / Q000188:drug therapy; D053764:Presenilin-1 / Q000235:genetics; D014611:Vaccination / Q000379:methods*; D000097382:CD68 Molecule
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014150:Antipsychotic Agents; D007464:Clioquinol; D005904:Glial Fibrillary Acidic Protein; D007074:Immunoglobulin G; D010446:Peptide Fragments; D053764:Presenilin-1; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C508853:PSEN1 protein, human; C075222:amyloid beta-protein (1-42)